2011 Fiscal Year Final Research Report
Development of less-side effect intravesical nanoparticle BCG therapy
| Project/Area Number |
20591848
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Hirosaki University |
|---|
Principal Investigator |
MORI Kazuyuki 弘前大学, 大学院・医学研究科, 助教 (40266903)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OHYAMA Chikara 弘前大学, 大学院・医学研究科, 教授 (80282135)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
YANO Ikuya 日本ビーシージー製造株式会社, 研究開発顧問 (60047008)
|
|---|
| Project Period (FY) |
2008 – 2011
|
| Keywords | BCG / ナノパーティクルBCG / 膀胱癌 / 直接効果 |
|---|
| Research Abstract |
Intravesical BCG therapy is effective treatment for non-muscle invasive bladder cancer, however, side effect is remaining. Nanoparticle BCG was prepared by disrupting live BCG and sized 42 to 500 nm. Nanoparticle BCG had identical direct antitumor effect as live BCG, but had a different mechanism, had direct antitumor effect against live BCG-resistant cell lines, and did not influence to normal cell line. These results suggested that nanoparticle BCG might reduce side effect, and might be used to develop new therapeutic drugs against live BCG-failure cases, invasive bladder cancer, or other tissue cancer.
|
